Skip to main content
European Commission logo print header

Anti-Cancer Light-Controllable Antibody-Peptide Conjugates

Project description

Selectively enhancing antibodies through light irradiation

Monoclonal antibodies have been considered a significant weapon against cancer since the beginning of the 20th century. After decades of research, medicine has managed to eliminate their adverse reactions to patients and develop revolutionary cancer therapies. The EU-funded ALISE project will focus on the possibility of boosting the anticancer activity only in tumours. To this aim, researchers will design and synthesise light-controllable conjugates of monoclonal antibodies with peptides whose anticancer activity can be enhanced in tumours by irradiation with light. In this project, seven leading institutions with significant expertise, resources and knowledge on design, synthesis and preclinical study in this field will join forces to contribute to innovative and safer therapeutic strategies.

Objective

Project ALISE (Antibody Light-Induced Selectivity Enhancement) will integrate the expertise, resources and knowledge of participating Institutions focusing on design, synthesis and preclinical study of conjugates of monoclonal antibodies with peptides whose anti-cancer activity can be enhanced in tumours by irradiation with light (LC-APCs). The possibility to boost the anti-cancer activity only in tumours, multiplied by targeting cancer cells by antibodies will be a basis for innovative and safer therapeutic strategies. Four of seven participating Institutions successfully collaborated in the field of light-controllable anticancer peptides, but this Project will widen the scope of collaboration, both in terms of the research field and collaborating Institutions. The participating Institutions are complementary in their expertise and know-how: the University of Cambridge will contribute with its know-how in design and preparation of antibodies. Light controllable peptides will be designed at Latvian Institute of Organic Synthesis and Karlsruhe Institute of Technology, synthesized, then loaded onto the antibodies in Cambridge. Company Enamine will perform initial screening of the conjugates in vitro and assess their safety. National Cancer Institute of Ukraine will contribute with its expertise in immunology, Cancer Center Amsterdam – with its expertise and knowledge in preclinical and clinical oncology. Lumobiotics GmbH will complement the consortium with its expertise in drug development. Integration of this potential will be achieved through research staff exchange and other activities organized in five work packages: 1) design and synthesis of novel light-controllable peptides as anti-cancer antibody payloads; 2) preparation and characterization of peptide conjugates with a model antibody; 3) biological screening of model LC-APCs; 4) preclinical evaluation of the LC-APCs aiming at treatment of human PDAC; 5) management, training, communication, dissemination.

Coordinator

ENAMINE LIMITED LIABILITY COMPANY,RESEARCH AND PRODUCTION ENTERPRISE
Net EU contribution
€ 303 600,00
Address
78 CHERVONOTKATSKA STR.
02094 Kyiv
Ukraine

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 303 600,00

Participants (6)